Clinical Trials
23 trialsNCT03937830 2026-05-22
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05211323 2026-05-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06096779 2026-05-04
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT05992220 2025-02-21
ALERT-HCC
Asan Medical Center
Phase 2 Recruiting
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06492408 2024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06482801 2024-07-01
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT06408623 2024-05-10
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00335829 2021-08-13
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
Phase 2 Completed
NCT04627363 2020-11-13
HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
Sun Yat-sen University
Phase 2 Unknown
NCT00049322 2020-09-01
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00576199 2014-08-29
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00605722 2014-07-14
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02013830 2014-06-06
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00242502 2013-05-06
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT00659022 2011-09-12
Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
Radboud University Medical Center
Phase 2 Unknown
NCT00106054 2010-08-27
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Pfizer
Phase 2 Terminated